Form 4: Teva Pharmaceutical Executive Eric A. Hughes Reports Share Transactions
SEC Form 4 Filing
Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent sale of shares to cover tax obligations.
Summary
- On August 1, 2024, Eric A. Hughes, an Executive Vice President at Teva Pharmaceutical Industries, reported transactions involving ordinary shares and restricted share units.
- 52,742 restricted share units vested, each representing a contingent right to receive one ordinary share or its cash value.
- Hughes sold 24,537 ordinary shares at a weighted average price of $17.2507 per share to cover tax withholding obligations related to the vesting of the restricted share units.
- These shares were sold in multiple transactions at prices ranging from $17.2502 to $17.2550.
- Following these transactions, Hughes directly owns 45,060 ordinary shares and 105,486 restricted share units.
Sentiment
Score: 6
Explanation: Neutral sentiment as the document primarily reports routine executive share transactions related to compensation and tax obligations.
Future Outlook
The reporting person will have additional restricted share units vesting on August 1, 2025, and August 1, 2026.
Industry Context
Executive share transactions are a common occurrence in publicly traded companies and are often related to compensation packages. These transactions are subject to regulatory oversight to prevent insider trading.
Comparison to Industry Standards
- Executive compensation packages often include restricted share units that vest over time, aligning executive interests with long-term shareholder value.
- The sale of shares to cover tax obligations upon vesting is a standard practice among executives receiving equity compensation.
- Rule 10b5-1 trading plans are frequently used by corporate insiders to schedule stock sales in advance, providing a defense against potential insider trading allegations.
- Comparing Hughes' compensation and share ownership to peers at similar pharmaceutical companies would provide further context.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders as they are part of a pre-arranged trading plan and relate to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 2022-08-01 | Restricted share units were granted. |
| 2023-08-01 | 52,742 restricted share units vested. |
| 2023-11-13 | Reporting person adopted a Rule 10b5-1 trading plan. |
| 2024-08-01 | 52,742 restricted share units vested; shares sold to cover tax obligations. |
| 2025-08-01 | 52,742 restricted share units vesting. |
| 2026-08-01 | 52,744 restricted share units vesting. |
| 2024-08-05 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.